Core Viewpoint - Lijun Group reported a steady performance in its Q3 financial results, with revenue and net profit showing modest growth, indicating resilience in its operations and strong cash flow position [2][3]. Financial Performance - For the first three quarters, the company achieved a revenue of 9.116 billion yuan, a year-on-year increase of 0.38% - The net profit attributable to shareholders was 1.754 billion yuan, up 4.86% - Basic earnings per share reached 1.96 yuan, reflecting an 8.29% increase - In Q3 alone, revenue was 2.844 billion yuan, growing by 1.6%, while net profit was 473 million yuan [2]. Institutional Holdings - Lijun Group is a well-known blue-chip stock in A-shares, with notable institutional holdings - Hong Kong Central Clearing Limited and Guotai Asset Management increased their holdings by 2.999 million shares and 593,900 shares, respectively - One insurance company has also appeared among the top ten circulating shareholders [3]. Product Strategy and Innovation - The company focuses on core areas such as digestive, reproductive, and neurological health, continuously iterating and expanding its product offerings - It is also venturing into broader markets like anti-infection and chronic disease management through self-research and business development - The innovation pipeline is accelerating, with several key products nearing clinical trial phases, including NS-041 for epilepsy and depression, SG1001 for invasive aspergillosis, and LZM012 for psoriasis [4][5][6]. Clinical Research and Development - Lijun Group is advancing several first-class innovative drugs in various therapeutic areas - The company is conducting Phase II clinical trials for its epilepsy and depression drug, which is unique in China - In the anti-infection sector, SG1001 is in Phase II trials, marking a significant innovation after a decade without new drugs in this area - The company is also progressing in the autoimmune field with LZM012, which has shown promising results against established competitors [5][6]. Regulatory and Management Updates - On October 23, the company announced updates to its information disclosure management, president's work guidelines, and investor relations management systems, indicating a commitment to governance and transparency [6].

Core Insights - Lijun Group reported a revenue of approximately 9.116 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 0.38%, and a net profit attributable to shareholders of approximately 1.754 billion yuan, with a year-on-year increase of 4.86% [1] Group 1: Digestive System - The company is advancing its product pipeline in the digestive system sector, with the new generation acid-reducing drug JP-1366's tablet application accepted in August, and its injection form entering Phase II clinical trials [1] - The dual dosage forms of JP-1366 are expected to synergize with the existing PPI pipeline, further solidifying the company's competitive position in the digestive system market [1] Group 2: Assisted Reproduction - In the assisted reproduction field, the company's urine-derived follicle-stimulating hormone, Lishenbao, holds over 90% market share domestically, while the recombinant human follicle-stimulating hormone, Liyoubi, has been submitted for production approval [1] - The company introduced a new oral GnRH antagonist in Q3, enhancing its product matrix in assisted reproduction [1] Group 3: Mental and Neurological Disorders - The company has developed a product portfolio addressing multiple indications such as schizophrenia and depression, with a focus on innovative targets to tackle difficult-to-treat conditions [2] - The innovative drug NS-041 for epilepsy is currently in Phase II clinical trials, and a clinical trial application for depression has recently been accepted, soon entering Phase II [2] - Long-acting treatment options are being developed, including injectable formulations of aripiprazole and paliperidone, creating a comprehensive long-acting treatment matrix [2] Group 4: Future Growth Areas - The company is strategically expanding into broader market spaces such as anti-infection, autoimmune diseases, cardiovascular, and metabolic disorders [2] - In the anti-infection sector, the innovative drug SG1001 for invasive aspergillosis is undergoing Phase II clinical trials [2] - In the autoimmune field, the innovative biological drug IL-17A/F is conducting the first positive controlled Phase III clinical study for psoriasis in China, with plans to submit for market approval [2] - The metabolic area is seeing the semaglutide for diabetes under review for market approval, while the weight loss indication is in the late Phase III clinical stage [2] - In cardiovascular health, the innovative drug H001 capsule for preventing venous thromboembolism post-orthopedic surgery is in Phase II clinical trials, with no similar innovative drugs currently available in China [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 6.272 billion yuan in H1 2025, a slight decrease of 0.17% year-on-year, while the net profit attributable to the parent company was 1.281 billion yuan, reflecting a growth of 9.40% year-on-year [4] - The company maintains a strong gross margin of 66.02% and a net profit margin of 24.73%, with significant improvements in net profit margin by 3.17 percentage points year-on-year [4] - The company is expected to continue its differentiated innovation strategy, with projected net profits of 2.276 billion yuan, 2.521 billion yuan, and 2.801 billion yuan for the years 2025, 2026, and 2027 respectively, leading to an EPS of 2.52 yuan, 2.79 yuan, and 3.10 yuan per share [4] Financial Performance Summary - In H1 2025, the company's sales expenses ratio was 27.69%, management expenses ratio was 4.77%, and R&D expenses ratio was 6.89% [4] - The company’s chemical preparations generated 3.270 billion yuan in revenue, with notable performance in digestive products (1.351 billion yuan, +3.87%) and psychiatric products (0.317 billion yuan, +6.89%) [5] - The company’s diversified product matrix is advancing rapidly, with several innovative drugs in the pipeline, including a long-acting formulation of Aripiprazole and a small nucleic acid drug targeting uric acid production [6] Financial Projections - The company is projected to have a revenue of 12.247 billion yuan in 2025, with a year-on-year growth of 3.7% [7] - The projected P/E ratios for 2025, 2026, and 2027 are 16.4, 14.8, and 13.3 respectively, indicating a favorable valuation trend [7]

Group 1: Key Research Projects - LZM012 targets IL-17A/F for moderate to severe psoriasis and ankylosing spondylitis, showing superior efficacy compared to control in Phase III trials, with PASI100 as the primary endpoint [2][5] - LZHN2408 for gout with hyperuricemia has received clinical approval, currently in Phase I trials, focusing on safety and efficacy [2] - H001, an anticoagulant for post-operative venous thromboembolism, has completed Phase II trials, showing comparable efficacy to enoxaparin with lower bleeding risk [3][7] - NS-041, a new generation KCNQ2/3 activator for epilepsy, has completed Phase I and is moving to Phase II, with no similar drugs on the market [3] - SG1001 for invasive fungal infections has completed Phase I trials, addressing drug resistance issues [3] - JP-1366, a P-CAB for gastrointestinal disorders, has completed Phase III trials and is preparing for market application [3] Group 2: Market Potential and Commercialization - The global market for psoriasis treatments is significant, with ustekinumab sales exceeding $6 billion in 2022, and UCB's bimekizumab projected to grow from $150 million in 2023 to over $600 million in 2024 [6][7] - LZM012 is expected to receive approval by mid-2027, aligning with the annual medical insurance negotiations [7] Group 3: Safety and Efficacy Data - LZM012's 52-week safety data shows a lower adverse reaction rate compared to ustekinumab, with no additional safety concerns identified [5] - H001's Phase I results indicate good safety profiles with no gastrointestinal bleeding, and preliminary data shows its anticoagulant effect is comparable to enoxaparin [7]

R&D Progress and Key Projects - LZM012, targeting IL-17A/F, is the first IL-17A/F inhibitor to complete Phase III clinical trials in China, showing a PASI100 response rate of 49.5%, outperforming the control group at 40.2% [6][7] - LZHN2408, for gout with hyperuricemia, has received clinical approval and is currently in Phase I trials, demonstrating safety and efficacy in preclinical studies [3][8] - H001, an anticoagulant for post-surgical venous thromboembolism, has completed patient enrollment in Phase II trials, showing comparable efficacy to enoxaparin with lower bleeding risks [3][4] New Drug Development - NS-041, a new generation KCNQ2/3 activator for epilepsy, has completed Phase I trials and is set to enroll over 280 patients in Phase II, with no similar drugs currently on the market [4] - SG1001, targeting invasive fungal infections, has completed Phase I trials and is expected to address drug resistance issues [5] - JP-1366, a P-CAB product, has completed Phase III trials and will soon submit for market approval, filling a gap in the domestic P-CAB injection market [5] Strategic Initiatives - The company plans to introduce 6 new drug projects in 2024, with 5 being innovative drugs, focusing on consolidating its leading position in gastrointestinal and neurological fields [9][10] - The acquisition of Vietnam's IMP Company aims to enhance market presence in Southeast Asia, leveraging local production capabilities and distribution networks [11] Clinical Data and Market Potential - LZM012's Phase III data indicates a low adverse reaction rate compared to the control drug, with ongoing evaluations for additional indications and potential overseas licensing [7][10] - The small RNA technology platform is being developed to enhance drug delivery systems, with a focus on the gout project as a leading initiative [8] Efficiency Improvements - The company has reformed its R&D system to improve efficiency through strategic project management and resource allocation, focusing on high-quality advancements in key therapeutic areas [11]